173 related articles for article (PubMed ID: 7522510)
1. Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
Mulder NH; van der Graaf WT; Willemse PH; Koops HS; de Vries EG; Sleijfer DT
Br J Cancer; 1994 Oct; 70(4):681-3. PubMed ID: 7522510
[TBL] [Abstract][Full Text] [Related]
2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
3. Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.
Vuoristo MS
Melanoma Res; 1996 Aug; 6(4):331-6. PubMed ID: 8873054
[TBL] [Abstract][Full Text] [Related]
4. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma.
Buter J; Sleijfer DT; Willemse PH; van der Graaf WT; de Vries EG; Schraffordt Koops H; Mulder NH
Anticancer Res; 1994; 14(3B):1325-8. PubMed ID: 7520681
[TBL] [Abstract][Full Text] [Related]
6. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
[TBL] [Abstract][Full Text] [Related]
8. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
9. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
Mulder NH; Willemse PH; Schraffordt Koops H; de Vries EG; Sleijfer DT
Br J Cancer; 1990 Dec; 62(6):1006-7. PubMed ID: 2257203
[No Abstract] [Full Text] [Related]
10. Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.
Mulder NH; Sleijfer DT; de Vries EG; Schraffordt Koops H; Samson MJ; Willemse PH
J Cancer Res Clin Oncol; 1989; 115(1):93-5. PubMed ID: 2466036
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Hernberg MM; Hahka-Kemppinen MH; Pyrhönen SO
Melanoma Res; 2004 Dec; 14(6):493-500. PubMed ID: 15577320
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
Luikart SD; Kennealey GT; Kirkwood JM
J Clin Oncol; 1984 Mar; 2(3):164-8. PubMed ID: 6199481
[TBL] [Abstract][Full Text] [Related]
13. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Gershanovich ML; Akimov MA
Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
15. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
16. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
Falkson CI
Med Oncol; 1995 Mar; 12(1):35-40. PubMed ID: 8542245
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.
Mulder NH; Sleijfer DT; Smit JM; De Vries EG; Willemse PH; Koops HS
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):879-81. PubMed ID: 2429842
[TBL] [Abstract][Full Text] [Related]
18. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
[TBL] [Abstract][Full Text] [Related]
19. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
[TBL] [Abstract][Full Text] [Related]
20. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
